PHI with Werlhof-Wichmann syndrome
How does this condition affect your private health insurance?
Werlhof-Wichmann-Syndrom, also known as Immune Thrombocytopenia (ITP) or Werlhof's disease, is an autoimmune bleeding disorder characterized by a low platelet count (thrombocytopenia). The immune system mistakenly attacks and destroys platelets, which are essential for blood clotting. This leads to symptoms such as easy bruising, petechiae (small red spots), purpura (larger purple spots), nosebleeds, and gum bleeding. In severe cases, internal bleeding, including life-threatening intracranial hemorrhage, can occur. ITP can affect both children and adults, often presenting acutely in children and becoming chronic in adults. Diagnosis involves excluding other causes of thrombocytopenia.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Days to several weeks, depending on severity and treatment response.
Duration of Illness (Lifetime)
Can be a one-time acute event (especially in children) or a chronic, lifelong condition requiring ongoing management (more common in adults).
Cost of Treatment (Initial)
Highly variable, from hundreds of dollars for mild cases (monitoring) to tens of thousands for severe episodes requiring hospitalization, IVIG, or anti-D immunoglobulin.
Cost of Treatment (Lifetime)
For chronic cases, costs can range from thousands to hundreds of thousands of dollars over a lifetime, including medications, regular monitoring, and potential for multiple interventions like splenectomy or thrombopoietin receptor agonists.
Mortality Rate
Low overall (around 1-2% in adults, even lower in children), but significantly higher in cases with severe hemorrhage, particularly intracranial bleeding.
Risk of Secondary Damages
Moderate to high. Includes chronic fatigue, psychological impact, significant bleeding episodes requiring transfusions, and rare but severe organ damage from hemorrhage (e.g., brain injury).
Probability of Full Recovery
High in acute childhood ITP (70-80% within 6-12 months). In adults, spontaneous remission is less common (20-30%), but many achieve stable platelet counts with treatment, though complete recovery without ongoing management is lower (around 30-50%).
Underlying Disease Risk
Typically idiopathic (primary ITP), but approximately 10-20% of cases are secondary to other conditions such as autoimmune diseases (e.g., SLE), infections (e.g., HIV, HCV, H. pylori), lymphoproliferative disorders, or certain medications.